8-K: Xilio Therapeutics Stockholders Approve New Incentive Plan, Option Repricing

Xilio Therapeutics, Inc. stockholders approved a new 2025 Stock Incentive Plan and a one-time repricing of certain employee stock options at a special meeting on November 21, 2025.

Summary

• Stockholders of Xilio Therapeutics, Inc. approved the 2025 Stock Incentive Plan, which had been previously adopted by the Board of Directors.
• A one-time repricing of certain outstanding employee stock options was also approved by stockholders and implemented after market close on November 21, 2025.
• The exercise price for repriced stock options held by executive officers, including President and CEO Ren Russo, CFO and COO Christopher Frankenfield, and CMO Katarina Luptakova, was reduced to $1.50 per share.
• Original weighted-average exercise prices for these executive officers ranged from $4.10 to $5.76 per share.
• A condition of the repricing states that if a repriced option is exercised prior to the 12-month anniversary of the repricing date, the original exercise price must be paid, except in cases of death, disability, or a change in control of the Company.
• Stockholders also approved a proposal to adjourn the Special Meeting if necessary to solicit further proxies for the main proposals.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative from a pure shareholder value perspective due to the immediate dilution effect of the option repricing and the potential for future dilution from the new incentive plan. While these actions are positive for employee retention and motivation, they come at a cost to existing shareholders.

Positives

• The approval of the 2025 Stock Incentive Plan provides a framework for future equity compensation, which is crucial for attracting and retaining talent in the biotechnology sector.
• The one-time repricing of employee stock options, particularly for executive officers, is intended to re-incentivize key personnel, aligning their interests with potential future stock price appreciation from a lower base.
• The condition requiring the original exercise price for early exercise (within 12 months) provides a measure of protection against immediate 'flipping' of the repriced options, except under specific circumstances.

Negatives

• The repricing of stock options effectively reduces the strike price for a significant number of shares held by executives, potentially leading to increased compensation expense and dilution for existing shareholders.
• The new 2025 Stock Incentive Plan, while standard, allows for the issuance of additional shares, which could contribute to future shareholder dilution.

Risks

• Potential dilution of existing shareholder value due to the repricing of stock options and the future issuance of shares under the new 2025 Stock Incentive Plan.
• The condition for repriced options (original exercise price for early exercise) could disincentivize some option holders from exercising within the first 12 months, potentially delaying the realization of the intended incentive.

Future Outlook

The approval of the 2025 Stock Incentive Plan provides a mechanism for Xilio Therapeutics to continue using equity-based compensation to attract, retain, and motivate employees in the future. The repricing of existing options is intended to re-incentivize current employees, particularly executive officers, by making their options more valuable and potentially aligning their motivation with future stock price recovery or growth.

Management Comments

• The Board of Directors previously adopted the 2025 Stock Incentive Plan, subject to stockholder approval, indicating management's belief in its necessity for compensation strategy.
• The implementation of the repricing immediately following stockholder approval demonstrates management's intent to quickly re-align employee incentives.

Industry Context

In the biotechnology and pharmaceutical industries, equity compensation, including stock options and incentive plans, is a standard and critical tool for attracting and retaining highly skilled talent. Companies often face challenges in retaining employees when stock prices decline significantly, making option repricing a common, albeit sometimes controversial, strategy to restore the incentive value of equity awards. The approval of a new stock incentive plan is a routine corporate governance action to ensure a continuous pool of shares for future grants.

Comparison to Industry Standards

• The establishment of a new stock incentive plan is a standard practice across publicly traded companies, particularly in high-growth sectors like biotechnology, to ensure a continuous pool of equity for employee compensation.
• Stock option repricing, while not universally adopted, is a known strategy employed by companies, especially those in volatile sectors or after significant stock price declines, to re-incentivize employees whose options may be 'underwater' (exercise price higher than current market price).
• The specific condition requiring the original exercise price for early exercise within 12 months, except for specific events, is a common protective measure seen in some repricing programs to mitigate immediate arbitrage or short-term gains without sustained performance.

Corporate Governance

Related Party Transactions

• The one-time repricing of certain outstanding employee stock options directly benefits executive officers, including the President and CEO, CFO and COO, and CMO, by significantly reducing their option exercise prices.

Stakeholder Impact

• Shareholders: Potential for dilution due to the repricing of options and the new stock incentive plan, which could impact per-share value.
• Employees (especially executive officers): Significant positive impact through re-incentivization from lower option exercise prices, potentially improving morale and retention.
• Company: Enhanced ability to attract and retain key talent, which is critical for long-term success in the biotechnology sector.

Next Steps

• The 2025 Stock Incentive Plan is now effective and available for future equity grants.
• The repriced stock options are now subject to the new $1.50 exercise price, with the 12-month restriction period in effect.

Key Dates

Keywords

Stock Incentive Plan, Stock Option Repricing, Executive Compensation, Corporate Governance, Shareholder Vote, Equity Compensation, Xilio Therapeutics